<DOC>
	<DOCNO>NCT01210625</DOCNO>
	<brief_summary>The investigator hypothesize daily oral intake starch-entrapped alginate microspheres ( call Nutrabiotix fiber ) well tolerate , exhibit minimal `` typical '' side effect fiber ( e.g . bloating , loose stool , flatulence ) , use ideal vehicle deliver anti-oxidants/anti-inflammatory natural synthetic substances/agents ; promote gut health improve bowel habit , change gut microbiota increase production short chain fatty acid , especially butyrate , colon decrease production protein putrification ( prebiotic effect ) .</brief_summary>
	<brief_title>Starch-entrapped Microspheres Nutrabiotix Fiber Gut Health</brief_title>
	<detailed_description>The long-term objective research program show target colonic delivery natural specific fermentable carbohydrate maintain promote gut health change gut microbiota [ prebiotic effect ] , increase `` protective growth promote '' factor butyrate , enhance intestinal barrier function . These health-promoting function may prevent treat wide range disorder associate abnormal microbiota ( dysbiosis ) and/or disrupt gut barrier function . Examples disorder associate dysbiosis disrupt gut barrier ( leaky gut ) allergic disorder , inflammatory bowel disease , diverticular disease , colon polyp cancer , alcoholic liver disease , non-alcoholic steatohepatitis ( NASH- common liver disease USA ) , irritable bowel syndrome ( IBS , common GI illness US high loss productivity high rate utilization health care resource ) . Nutrabiotix fiber prebiotic able promote gut health change stool microbiota composition favor saccharolytic bacteria like Bifidobacteria diminish proteolytic bacteria like Clostridia . This change intestinal microbiota composition result increase product carbohydrate fermentation [ SCFA ] decrease product protein breakdown [ indoles phenol ] stool . Also , fiber well tolerate without side effect effective fiber increase stool bulk regulates bowel movement .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Psyllium</mesh_term>
	<mesh_term>Calcium polycarbophil</mesh_term>
	<criteria>Healthy , asymptomatic 18 65 year subject BMI 2030 self describe unsatisfactory bowel habit 1 . Abnormalities CBC ( Hgb &lt; 12 g/dL , platelet count &lt; 100 000 , WBC &lt; 4000 &gt; 10 000 ) ; 2 . Abnormal liver function test ( ALT , AST , alkaline phosphatase , bilirubin &gt; 1.5 time normal range ) ; 3 . Abnormal renal function test ( BUN creatinine &gt; 1.5 time normal range ) ; 4 . Low serum albumin ( &lt; 3 g/dL ) ; 5 ) Abnormal TSH level ; ( 6 ) High CRP ; ( 7 ) Significant GI symptom ( except constipation occasional rectal bleeding due hemorrhoid ) ; ( 8 ) Prior intestinal resection ; ( 9 ) Patient history GI diseases [ except hemorrhoid occasional ( &lt; 3 time week ) heartburn ] ; ( 10 ) Antibiotic use within last 12 week prior enrollment ; ( 11 ) Lean ( BMI &lt; 25 ) obese ( BMI &gt; 30 ) subject obesity could associate abnormal microbiota ; ( 12 ) Significant cardiac respiratory disease ( define require daily medication management disease ) ; ( 13 ) Severe hypertension ( define uncontrolled hypertension spite therapy , requirement one medication treat hypertension ; wellcontrolled , mild hypertension may include ) ; ( 14 ) Insulinrequiring and/or poorly control diabetes ( wellcontrolled diabetic HbA1c &lt; 6 may enrol ) ; ( 15 ) Significant psychological disorder ; ( 16 ) Drug and/or alcohol abuse ; ( 17 ) Unwillingness consent study ; ( 18 ) Plan major change dietary habit follow 5 month ; ( 19 ) Subjects young 18 old 65 . Older subject exclude initial study high comorbidity old subject . Children exclude initial Phase I study safety establish ; ( 20 ) Pregnant lactate woman due lack information safety product pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Constipation</keyword>
</DOC>